NCT00370981

Exploratory Study of Pagoclone in Men With Premature Ejaculation.

A Four-arm, Randomized, Double-blind, Parallel, Placebo-controlled Exploratory Study of Pagoclone 0.15mg, 0.30mg, and 0.60mg in Men With Primary Premature Ejaculation.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (planned)
• Sponsor: Endo Pharmaceuticals · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.

Detailed description

The primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone (0.15 mg, 0.30 mg, and 0.60 mg) versus placebo on intravaginal ejaculation latency time (IELT) male patients with primary premature ejaculation.

Conditions

• Premature Ejaculation

Interventions

Type	Name	Description
DRUG	pagoclone

Timeline

• Start date: 2006-07-01
• Primary completion: 2006-07-01
• Completion: 2006-10-01
• First posted: 2006-09-01
• Last updated: 2013-12-27

Locations

16 sites across 1 country: United States